CLBS
Price:
$0.4264
Market Cap:
$3.35M
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences...[Read more]
Industry
Biotechnology
IPO Date
1995-11-03
Stock Exchange
NASDAQ
Ticker
CLBS
According to Caladrius Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.08. This represents a change of -47.64% compared to the average of -2.07 of the last 4 quarters.
The mean historical PE Ratio of Caladrius Biosciences, Inc. over the last ten years is -0.96. The current -1.08 PE Ratio has changed 11.21% with respect to the historical average. Over the past ten years (40 quarters), CLBS's PE Ratio was at its highest in in the June 2020 quarter at 0.89. The PE Ratio was at its lowest in in the June 2017 quarter at -5.13.
Average
-0.96
Median
-0.51
Minimum
-2.71
Maximum
-0.06
Discovering the peaks and valleys of Caladrius Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 760.29%
Maximum Annual PE Ratio = -0.06
Minimum Annual Increase = -82.56%
Minimum Annual PE Ratio = -2.71
Year | PE Ratio | Change |
---|---|---|
2021 | -0.47 | -82.56% |
2020 | -2.71 | 102.61% |
2019 | -1.34 | -37.24% |
2018 | -2.13 | 9.55% |
2017 | -1.95 | 249.92% |
2016 | -0.56 | 760.29% |
2015 | -0.06 | -53.00% |
2014 | -0.14 | 13.77% |
2013 | -0.12 | 35.38% |
2012 | -0.09 | 144.87% |
The current PE Ratio of Caladrius Biosciences, Inc. (CLBS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.51
5-year avg
-1.72
10-year avg
-0.96
Caladrius Biosciences, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Caladrius Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Caladrius Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Caladrius Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Caladrius Biosciences, Inc. (CLBS)?
What is the highest PE Ratio for Caladrius Biosciences, Inc. (CLBS)?
What is the 3-year average PE Ratio for Caladrius Biosciences, Inc. (CLBS)?
What is the 5-year average PE Ratio for Caladrius Biosciences, Inc. (CLBS)?
How does the current PE Ratio for Caladrius Biosciences, Inc. (CLBS) compare to its historical average?